Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

Osteoporosis International

Volumn 21, Issue 5, 2010, Pages 837-846

  Kendler, D L ^a   Bessette, L ^b   Hill, C D ^c   Gold, D T ^d   Horne, R ^e   Varon, S F ^f,g   Borenstein, J ^g   Wang, H ^g   Man, H S ^h   Wagman, R B ^g,i   Siddhanti, S ^g   MacArios, D ^g   Bone, H G ^j  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c RTI HEALTH SOLUTIONS   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF LONDON   (United Kingdom)

^f ALLERGAN INC   (United States)

^g AMGEN INC   (United States)

^h AMGEN LTD   (United Kingdom)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Michigan Bone and Mineral Clinic   (United States)

more..

Author keywords

Injection; Osteoporosis; Preference; Questionnaire; Satisfaction; Tablet

Indexed keywords

ALENDRONIC ACID; DENOSUMAB;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG PREFERENCE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PREFERENCE AND SATISFACTION QUESTIONNAIRE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT PREFERENCE; PATIENT SATISFACTION; PSYCHOMETRICS; RANK LIGAND; TABLETS;

EID: 77951258966     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1023-x     Document Type: Article

References (45)

1. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 487 497 10.1056/NEJMra050100 1:CAS:528:DC%2BD2MXntVCisL0%3D 16079372 (Pubitemid 41127293)
2. C Wahl JP Gregoire K Teo, et al. 2005 Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes Healthc Qual 8 65 70
3. P Kothawala E Badamgarav S Ryu, et al. 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493 1501 10.4065/82.12.1493 18053457 (Pubitemid 350211697)
4. JY Reginster V Rabenda A Neuprez 2006 Adherence, patient preference and dosing frequency: understanding the relationship Bone 38 S2 S6 10.1016/j.bone.2006.01.150 1:STN:280:DC%2BD287mvFOitA%3D%3D 16520104
5. ES Siris ST Harris CJ Rosen, et al. 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 10.4065/81.8.1013 16901023
6. DT Gold BC Martin JR Frytak, et al. 2007 A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis Curr Med Res Opin 23 585 594 10.1185/030079906X167615 1:CAS:528:DC%2BD2sXkt1Wku7Y%3D 17355739 (Pubitemid 46456906)
7. CH van den Boogaard NS Breekveldt-Postma SE Borggreve, et al. 2006 Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study Curr Med Res Opin 22 1757 1764 10.1185/030079906X132370 16968579 (Pubitemid 44449232)
8. JJ Caro KJ Ishak KF Huybrechts, et al. 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003 1008 10.1007/s00198-004-1652-z 15167989 (Pubitemid 40064656)
9. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928 10.1016/j.bone.2005.10.022 16330270 (Pubitemid 44498580)
10. JS McCombs P Thiebaud C McLaughlin-Miley, et al. 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287 10.1016/j.maturitas.2004.02.005 1:CAS:528:DC%2BD2cXltVCiu7g%3D 15207894 (Pubitemid 38781153)
11. A Papaioannou G Ioannidis JD Adachi, et al. 2003 Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database Osteoporos Int 14 808 813 10.1007/s00198-003- 1431-2 1:CAS:528:DC%2BD3sXosFWrsLg%3D 14523610 (Pubitemid 37462130)
12. RS Stafford RL Drieling AL Hersh 2004 National trends in osteoporosis visits and osteoporosis treatment, 1988-2003 Arch Intern Med 164 1525 1530 10.1001/archinte.164.14.1525 15277283 (Pubitemid 38970472)
13. J Watson L Wise J Green 2007 Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005 Eur J Clin Pharmacol 63 843 849 10.1007/s00228-007-0320-6 17598097 (Pubitemid 47237896)
14. DM Black DE Thompson DC Bauer, et al. 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 4118 4124 10.1210/jc.85.11.4118 1:CAS:528:DC%2BD3cXotlWnurw%3D 11095442 (Pubitemid 32055362)
15. SR Cummings DM Black DE Thompson, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082 10.1001/jama.280.24.2077 1:CAS:528:DyaK1MXjsVWruw%3D%3D 9875874 (Pubitemid 29014065)
16. D Kendler AW Kung H Fuleihan Gel, et al. 2004 Patients with osteoporosis prefer once weekly to once daily dosing with alendronate Maturitas 48 243 251 10.1016/j.maturitas.2003.12.012 1:CAS:528:DC%2BD2cXltVCiu7o%3D 15207890 (Pubitemid 38781149)
17. JA Simon EM Lewiecki ME Smith, et al. 2002 Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study Clin Ther 24 1871 1886 10.1016/S0149-2918(02)80085-6 1:CAS:528:DC%2BD38Xpsleku7w%3D 12501880 (Pubitemid 35440956)
18. TL Burgess Y Qian S Kaufman, et al. 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts J Cell Biol 145 527 538 10.1083/jcb.145.3.527 1:CAS:528:DyaK1MXivFKntr8%3D 10225954 (Pubitemid 29215717)
19. P Kostenuik H Nguyen J McCabe, et al. 2009 Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (murine/human) RANKL J Bone Miner Res 24 182 195 10.1359/jbmr.081112 1:CAS:528:DC%2BD1MXitlWktro%3D 19016581
20. DL Lacey E Timms HL Tan, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176 10.1016/S0092-8674(00)81569-X 1:CAS:528:DyaK1cXivVyhtrg%3D 9568710 (Pubitemid 28180851)
21. HG Bone MA Bolognese CK Yuen, et al. 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women J Clin Endocrinol Metab 93 2149 2157 10.1210/jc.2007-2814 1:CAS:528:DC%2BD1cXntFamtrg%3D 18381571 (Pubitemid 351831529)
22. SR Cummings MR McClung C Christiansen, et al. 2008 The effects of denosumab on fracture risk in women with osteoporosis Osteoporos Int 20 167
23. EM Lewiecki PD Miller MR McClung, et al. 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density J Bone Miner Res 22 1832 1841 10.1359/jbmr.070809 1:CAS:528:DC%2BD2sXhsVyjtrjF 17708711 (Pubitemid 351229299)
24. MR McClung EM Lewiecki SB Cohen, et al. 2006 Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821 831 10.1056/NEJMoa044459 1:CAS:528:DC%2BD28Xhsl2gs7o%3D 16495394 (Pubitemid 43290920)
25. PD Miller MA Bolognese EM Lewiecki, et al. 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 222 229 10.1016/j.bone.2008.04.007 1:CAS:528:DC%2BD1cXosVOitrk%3D 18539106
26. R Emkey W Koltun K Beusterien, et al. 2005 Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) Curr Med Res Opin 21 1895 1903 10.1185/030079905X74862 1:CAS:528:DC%2BD28XhtF2juro%3D 16368038 (Pubitemid 41803098)
27. P Hadji H Minne M Pfeifer, et al. 2008 Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II) Joint Bone Spine 75 303 310 10.1016/j.jbspin.2007.07.011 1:CAS:528:DC%2BD1cXnsFWkt7w%3D 18069036
28. M McClung R Recker P Miller, et al. 2007 Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate Bone 41 122 128 10.1016/j.bone.2007.03.011 1:CAS:528:DC%2BD2sXmsFKkurc%3D 17468062 (Pubitemid 46901056)
29. DT Gold R Horne C Hill, et al. 2008 Development, reliability, and validity of a new preference satisfaction questionnaire J Bone Miner Res 23 S210 S211
30. DL Kendler CL Benhamou JP Brown, et al. 2008 Effects of denosumab in postmenopausal women transitioning from alendronate therapy in comparison with continued alendronate Osteoporos Int 9 Suppl 2 S385 S386
31. JP Brown RL Prince C Deal, et al. 2008 Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 10.1359/jbmr.080910 18021006
32. JA Cramer DT Gold SL Silverman, et al. 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023 1031 10.1007/s00198-006-0322-8 1:CAS:528:DC%2BD2sXntVOlsrY%3D 17308956 (Pubitemid 47019996)
33. JY Reginster N Burlet 2006 Osteoporosis: a still increasing prevalence Bone 38 S4 S9 10.1016/j.bone.2005.11.024 16455317 (Pubitemid 43190767)
34. DH Solomon J Avorn JN Katz, et al. 2005 Compliance with osteoporosis medications Arch Intern Med 165 2414 2419 10.1001/archinte.165.20.2414 16287772 (Pubitemid 41640855)
35. DC Saltman GP Sayer NA O'Dea 2006 Dosing frequencies in general practice-whose decision and why? Aust Fam Physician 35 915 919 17099815
36. AJ Claxton J Cramer C Pierce 2001 A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 1296 1310 10.1016/S0149-2918(01)80109-0 1:STN:280:DC%2BD3MrhtVKktA%3D%3D 11558866 (Pubitemid 32804122)
37. E Brankin M Walker N Lynch, et al. 2006 The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases Curr Med Res Opin 22 1249 1256 10.1185/030079906X112688 1:CAS:528:DC%2BD28XotlKgtLw%3D 16834823 (Pubitemid 44085576)
38. JA Cramer MM Amonkar A Hebborn, et al. 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460 10.1185/030079905X61875 1:CAS:528: DC%2BD2MXhtFKqu7zP 16197664 (Pubitemid 41368578)
39. JA Cramer NO Lynch AF Gaudin, et al. 2006 The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France Clin Ther 28 1686 1694 10.1016/j.clinthera.2006.10.013 1:CAS:528:DC%2BD28XhtlartrvP 17157124 (Pubitemid 44838898)
40. MP Ettinger R Gallagher PE MacCosbe 2006 Medication persistence with weekly versus daily doses of orally administered bisphosphonates Endocr Pract 12 522 528 17002926 (Pubitemid 46456039)
41. J Payer Z Killinger I Sulkova, et al. 2008 Preferences of patients receiving bisphosphonates-how to influence the therapeutic adherence Biomed Pharmacother 62 122 124 10.1016/j.biopha.2007.07.005 1:CAS:528: DC%2BD1cXitVKitLw%3D 17888616 (Pubitemid 351215813)
42. A Cooper J Drake E Brankin 2006 Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study Int J Clin Pract 60 896 905 10.1111/j.1742-1241.2006.01059.x 1:CAS:528:DC%2BD28XpvVemsLg%3D 16800837 (Pubitemid 44082279)
43. K Saag R Lindsay A Kriegman, et al. 2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density Bone 40 1238 1243 10.1016/j.bone.2007.01.016 1:CAS:528:DC%2BD2sXktF2nsrg%3D 17347063 (Pubitemid 46550991)
44. R Horne C Kovacs C Katlama, et al. 2009 Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives? AIDS Res Ther 6 2 10.1186/1742-6405-6-2 19196474
45. K Gruffydd-Jones CA Hood DB Price 1997 A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice Cephalalgia 17 31 36 10.1046/j.1468-2982.1997.1701031.x 1:STN:280:DyaK2s3gtlOlsw%3D%3D 9051333 (Pubitemid 27101418)